Blom, M <br/><br/>
Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.  [electronic resource] 

 -  Arthritis care & research  Sep 2010 
 - 1335-41 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2151-4658 
<br/><br/><label>Standard No.: </label>10.1002/acr.20211  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Adult<br/>Aged<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antirheumatic Agents--administration & dosage<br/>Arthritis, Rheumatoid--drug therapy<br/>Dose-Response Relationship, Drug<br/>Etanercept<br/>Female<br/>Humans<br/>Immunoglobulin G--administration & dosage<br/>Infliximab<br/>Male<br/>Middle Aged<br/>Outcome Assessment, Health Care<br/>Receptors, Tumor Necrosis Factor--administration & dosage<br/>Registries<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors